Sanofi’s Venglustat Met All Primary Endpoints in a Phase 3 Study of Type 3 Gaucher Disease

Today’s Highlights February 2, 2026

Sanofi
Sanofi (SNY) - Paris, February 2, 2026 , positive results from the LEAP2MONO phase 3 study (clinical study identifier: This content is for paid subscribers.

Please click here to subscribe or here to log in.

Today’s Highlights

Sanofi (SNY)

February 2, 2026

Exclusive Market Insight

& Scientific analysis

Sanofi’s Venglustat Met All Primary Endpoints in a Phase 3 Study of Type 3 Gaucher Disease

Other Articles